Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DML61S4)

Drug Name
ARQ-151 Drug Info
Cross-matching ID
PubChem CID
449193
TTD Drug ID
DST04F

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Oxidative phosphorylation 2.55 0.00e+0 93/133 (69.92%) NDUFB5;COX7B;ATP5F1C;...
Ribosome 2.46 0.00e+0 113/158 (71.52%) MRPS16;RPS4Y1;RPS5;...
Parkinson disease 2.19 0.00e+0 176/249 (70.68%) NDUFB5;COX7B;ATP5F1C;...
DNA replication 2.01 1.64e-3 34/36 (94.44%) PCNA;POLE2;RNASEH2A;...
Thermogenesis 1.95 2.62e-3 173/232 (74.57%) NDUFB5;COX7B;ATP5F1C;...
Diabetic cardiomyopathy 1.90 7.63e-3 162/203 (79.8%) NDUFB5;COX7B;ATP5F1C;...
Cell cycle 1.89 6.54e-3 110/124 (88.71%) CHEK2;E2F2;CDK1;...
Huntington disease 1.87 5.72e-3 233/306 (76.14%) NDUFB5;COX7B;ATP5F1C;...
Non-alcoholic fatty liver disease 1.84 5.82e-3 126/155 (81.29%) NDUFB5;COX7B;CYCS;...
Mismatch repair 1.82 6.54e-3 22/23 (95.65%) PCNA;RPA3;RFC2;...
Amyotrophic lateral sclerosis 1.70 2.20e-2 267/364 (73.35%) NDUFB5;COX7B;ATP5F1C;...
Prion disease 1.69 2.62e-2 209/273 (76.56%) NDUFB5;COX7B;ATP5F1C;...
Coronavirus disease 1.68 2.42e-2 215/232 (92.67%) C3;RPS4Y1;OAS1;...
Base excision repair 1.67 2.76e-2 29/33 (87.88%) PCNA;POLE2;FEN1;...
Citrate cycle (TCA cycle) 1.65 2.92e-2 30/30 (100%) DLD;SDHD;SUCLG1;...
Cardiac muscle contraction 1.63 3.93e-2 64/87 (73.56%) COX7B;FXYD2;COX5B;...
Proteasome 1.61 4.46e-2 44/46 (95.65%) PSMA6;PSMA3;PSME1;...
Hepatocellular carcinoma -1.68 4.58e-2 135/168 (80.36%) SMAD3;MET;DDB2;...
Sphingolipid signaling pathway -1.69 4.36e-2 106/119 (89.08%) PPP2R5B;FYN;BAX;...
B cell receptor signaling pathway -1.72 3.09e-2 71/81 (87.65%) GSK3B;LILRB5;LILRB2;...
Focal adhesion -1.73 3.02e-2 180/201 (89.55%) SOS1;COL4A5;PRKCB;...
Notch signaling pathway -1.78 1.77e-2 49/59 (83.05%) EP300;JAG2;PSEN2;...
GnRH secretion -1.78 1.90e-2 60/64 (93.75%) KCNJ3;LHB;PLCB2;...
Glycerolipid metabolism -1.78 1.72e-2 44/61 (72.13%) LIPF;PLPP3;AGPAT2;...
Ferroptosis -1.80 1.87e-2 36/41 (87.8%) PRNP;GCLM;GCLC;...
Other glycan degradation -1.82 1.37e-2 13/18 (72.22%) NEU1;GLB1;HEXA;...
C-type lectin receptor signaling pathway -1.82 1.53e-2 93/104 (89.42%) RAF1;MAPK9;PLCG2;...
Autophagy -1.85 1.20e-2 113/169 (66.86%) RRAGD;ITPR1;IRS2;...
Steroid biosynthesis -1.89 7.85e-3 19/20 (95%) TM7SF2;SOAT1;DHCR7;...
Mitophagy -1.90 6.87e-3 56/68 (82.35%) OPTN;BCL2L13;CALCOCO2;...
Fatty acid biosynthesis -1.91 8.24e-3 16/18 (88.89%) ACACA;FASN;ACSL3;...
Glycerophospholipid metabolism -1.93 6.87e-3 71/98 (72.45%) PLA2G10;CHPT1;PLD2;...
Phosphatidylinositol signaling system -1.94 9.16e-3 82/97 (84.54%) MTMR3;PIP5K1A;PLCB2;...
Primary immunodeficiency -1.98 6.87e-3 33/38 (86.84%) TAP1;RAG2;ADA;...
VEGF signaling pathway -2.15 0.00e+0 50/59 (84.75%) PRKCB;MAPKAPK3;RAF1;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H